NDAINJECTIONINJECTABLE
Approved
Feb 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VASOTEC (enalaprilat) by Pfizer is mechanism of action intravenous enalaprilat, or oral enalapril, after hydrolysis to enalaprilat, inhibits ace in human subjects and animals. Approved for hypertension. First approved in 1988.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOTEC (enalaprilat) is an intravenous ACE inhibitor approved in 1988 for hypertension management. It works by inhibiting angiotensin-converting enzyme, reducing plasma angiotensin II and decreasing vasopressor activity and aldosterone secretion. The drug is indicated for patients requiring rapid blood pressure reduction in acute hypertensive settings.
LOE Approaching
As LOE approaches, the VASOTEC brand team is likely consolidating and transitioning focus to lifecycle extension or supporting generic transition strategies.
Mechanism of Action
Mechanism of Action Intravenous enalaprilat, or oral enalapril, after hydrolysis to enalaprilat, inhibits ACE in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates…
Indications (1)
Worked on VASOTEC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.